FRANKFURT, Oct 25 (Reuters) - Sanofi's finance chief on Friday said the company won't be affected by Novo Nordisk's controlling shareholder's decision to acquire contract drug manufacturer Catalent , adding the deal made sense for its rival.
"They desperately need capacity so it makes sense for them," Sanofi CFO Francois-Xavier Roger said in a media call after the release of third-quarter results.
He added Novo paid a "very heavy price to get access to the capacity", given very strong demand for weight-loss drugs.
Swiss drugmaker Roche on Wednesday joined peer Eli Lilly in voicing concern over the planned Catalent takeover, saying it could hit competition in the booming weight-loss drug industry.
(Reporting by Ludwig Burger)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.